NCT04611971View on ClinicalTrials.gov

A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 2

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

October 27, 2020

Primary Completion Date

May 6, 2021

Study Completion Date

May 6, 2021

Conditions
Healthy
Interventions
DRUG

Benlysta

Benlysta injection will be administered subcutaneously.

DRUG

Candin

Candin will be administered intradermally along with NaCl solution.

Trial Locations (1)

2170

Clinical Pharmacology Unit, Merksem

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT04611971 - A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 2 | Biotech Hunter | Biotech Hunter